The startup, which was formed from the nonprofit Accumulus Synergy last August, has developed a network linking pharmaceutical and biotech firms to regulators in over 70 countries. The newly introduced Connector allows access to this network without leaving the systems currently in use by companies.
Securing drug approvals in multiple countries at once requires submitting identical information to various national regulatory bodies, each with unique systems, formats, and timelines. For most pharmaceutical and biotech firms, this involves manual reconciliation between internal systems, substantial effort duplication, and extended submission timelines beyond what the core science demands.
Accumulus Technologies, a San Francisco-based SaaS firm that emerged from the regulatory-tech nonprofit Accumulus Synergy last August, has been crafting a cloud platform to streamline this bottleneck. Today, it unveiled the Accumulus Connector, a feature designed to make the platform accessible directly within the systems companies already operate.
The heart of Accumulus Technologies’ service is its regulatory network: a real-time platform linked to more than 70 national regulatory authorities, compared to the over 60 countries covered during the August 2025 spinout. Drug and biotech firms use this platform for managing simultaneous submissions across regions, facilitating what the industry terms “reliance pathways”, allowing regulators in one nation to utilize another country’s review work, shortening the time a therapy takes to reach patients in otherwise deprioritized markets.
The Sanofi case announced in November 2024, while the platform remained within Accumulus Synergy, demonstrated the practical application: multi-regulator submissions managed simultaneously through a single interface instead of separate coordination across regions.
The Connector expands that network into a new integration layer. Previously, using the Accumulus platform necessitated working within the platform itself, with data transitioning between it and the company’s systems of record through manual reconciliation or custom integration processes. The Connector makes the network accessible directly from those existing systems, ERP platforms, regulatory information management systems, document management tools, enabling real-time, bi-directional data movement between them and the regulatory network.
Chanille Juneau, Chief Product and Technology Officer, described the design objective as accommodating organizations “where they are,” without requiring migration from established infrastructures. The Connector is offered to existing Accumulus platform subscribers.
The company is also presenting the integration layer as operating in both directions: not only do pharma firms connect their systems to regulators, but regulators can connect their systems into the Accumulus platform as well, creating what is described as a “bi-directional network across industry and authorities.”
Accumulus Technologies is a newly formed commercial entity, having officially separated from Accumulus Synergy only eight months ago, though the platform it commercializes was launched in February 2024, and the underlying nonprofit spent several years building the ecosystem, supported by founding sponsors from major global pharmaceutical companies. Francisco Nogueira, who developed the platform within Accumulus Synergy, serves as CEO. The Connector launch marks the company’s first significant platform capability announcement since the spinout, reflecting the central challenge in its commercial model: marketing SaaS infrastructure to an industry that is inherently conservative, highly regulated, and historically has treated data exchange between companies and regulators as sensitive enough to necessitate a nonprofit intermediary for building the trust infrastructure initially.